Wake Forest University Health Sciences
Tirzepatide produces rapid, clinically meaningful weight loss. In older adults, however, substantial weight reduction may accelerate loss of bone and muscle, increase frailty risk, and compound age-related skeletal vulnerability. The purpose of this study is to find out if taking risedronate along with tirzepatide preserves musculoskeletal health during tirzepatide-associated weight loss.
Tirzepatide produces rapid, clinically meaningful weight loss. Weight loss of this magnitude is accompanied by increased bone turnover, hip bone loss, and loss of fat-free mass. Risedronate is a bisphosphonate therapy that inhibits osteoclast-mediated bone resorption and has an established monthly oral regimen. Pilot bariatric-surgery data from the investigative team support feasibility \[1\], attenuation of bone loss and resorption \[2\], and a signal for preservation of appendicular lean mass \[3\]. This single-center, 12-month, randomized, double-blind, placebo-controlled, parallel-group ph…
Inclusion Criteria: * BMI≥30 or 27.0-29.9 kg/m2 plus one weight related co-morbidity * Weight stability (within 5% in past 3 months) * Community dwelling * English speaking * Able to attend regular in person appointments, willingness to take tirzepatide and risedronate medication, and willing to provide informed consent Exclusion Criteria: * Weight \>450 lbs (DXA limit) * Disordered alcohol or substance use * Eating disorder in past 5 years * \>1 fall (injurious or non-injurious) in past year or prior fragility fracture * Osteoporosis (self-report, medication use, or T-score ≤ -2.5 on hip o…
Tirzepatide 2.5 mg weekly for 4 weeks, then 5 mg, 7.5 mg, and 10 mg at 4-week intervals as tolerated; continue 10 mg weekly through month 12.
Risedronate 150 mg orally once monthly for 12 doses
risedronate matching placebo orally once monthly for 12 doses
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.